메뉴 건너뛰기




Volumn 107, Issue 7, 2006, Pages 1525-1529

Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia

Author keywords

9 nitrocamptothecin; Chronic myelomonocytic leukemia; Myelodysplastic syndrome

Indexed keywords

9 NC; DNA TOPOISOMERASE INHIBITOR; RUBITECAN;

EID: 33749633145     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22186     Document Type: Article
Times cited : (23)

References (20)
  • 1
    • 3042821845 scopus 로고    scopus 로고
    • Novel therapies for myelodysplastic syndromes
    • Faderl S, Kantarjian H. Novel therapies for myelodysplastic syndromes. Cancer. 2004;101:226-241.
    • (2004) Cancer , vol.101 , pp. 226-241
    • Faderl, S.1    Kantarjian, H.2
  • 2
    • 0030897009 scopus 로고    scopus 로고
    • International scoring system for evaluating prognosis in myelodysplastic syndromes
    • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
    • (1997) Blood , vol.89 , pp. 2079-2088
    • Greenberg, P.1    Cox, C.2    Lebeau, M.M.3
  • 3
    • 0037093195 scopus 로고    scopus 로고
    • Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B
    • Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440.
    • (2002) J Clin Oncol , vol.20 , pp. 2429-2440
    • Silverman, L.R.1    Demakos, E.P.2    Peterson, B.L.3
  • 4
    • 33646071894 scopus 로고    scopus 로고
    • Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
    • Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794-803.
    • (2006) Cancer , vol.106 , pp. 1794-1803
    • Kantarjian, H.1    Issa, J.P.2    Rosenfeld, C.S.3
  • 5
    • 33644553459 scopus 로고    scopus 로고
    • Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
    • Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006;106:1099-1109.
    • (2006) Cancer , vol.106 , pp. 1099-1109
    • Kantarjian, H.1    Beran, M.2    Cortes, J.3
  • 6
    • 13444256401 scopus 로고    scopus 로고
    • Efficacy of lenalidomide in myelodysplastic syndromes
    • List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-557.
    • (2005) N Engl J Med , vol.352 , pp. 549-557
    • List, A.1    Kurtin, S.2    Roe, D.J.3
  • 7
    • 23844522604 scopus 로고    scopus 로고
    • Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 study
    • List AF, Dewald G, Bennett J, et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study [Abstract 5]. J Clin Oncol. 2005;23:2s.
    • (2005) J Clin Oncol , vol.23
    • List, A.F.1    Dewald, G.2    Bennett, J.3
  • 8
    • 0141482004 scopus 로고    scopus 로고
    • Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
    • Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379-2386.
    • (2003) Blood , vol.102 , pp. 2379-2386
    • Kantarjian, H.1    Gandhi, V.2    Cortes, J.3
  • 9
    • 0030051722 scopus 로고    scopus 로고
    • Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia
    • Feldman EJ, Seiter KP, Ahmed T, et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia. 1996;10:40-42.
    • (1996) Leukemia , vol.10 , pp. 40-42
    • Feldman, E.J.1    Seiter, K.P.2    Ahmed, T.3
  • 10
    • 0036464647 scopus 로고    scopus 로고
    • Prognostic factors and scoring systems in chronic myelomonocytic leukemia: A retrespective analysis of 213 patients
    • Onida F, Kantarjian H, Smith T, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrespective analysis of 213 patients. Blood. 2002;99:840-849.
    • (2002) Blood , vol.99 , pp. 840-849
    • Onida, F.1    Kantarjian, H.2    Smith, T.3
  • 11
    • 0141956034 scopus 로고    scopus 로고
    • CMML: A biologically distinct myeloproliferative disease
    • Cortes J. CMML: a biologically distinct myeloproliferative disease. Curr Hematol Rep. 2003;2:202-208.
    • (2003) Curr Hematol Rep , vol.2 , pp. 202-208
    • Cortes, J.1
  • 12
    • 0032784783 scopus 로고    scopus 로고
    • World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997
    • Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
    • (1999) J Clin Oncol , vol.17 , pp. 3835-3849
    • Harris, N.L.1    Jaffe, E.S.2    Diebold, J.3
  • 13
    • 10144234806 scopus 로고    scopus 로고
    • Topotecan, a topoisomerase I inhibitor, is active in treatment of myelodysplastic syndrome and chronic myelomonocytic leuikemia
    • Beran M, Kantarjian H, O'Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in treatment of myelodysplastic syndrome and chronic myelomonocytic leuikemia. Blood. 1996;88:2473-2479.
    • (1996) Blood , vol.88 , pp. 2473-2479
    • Beran, M.1    Kantarjian, H.2    O'Brien, S.3
  • 14
    • 0141455145 scopus 로고    scopus 로고
    • Phase I study of oral topotecan in hematological malignancies
    • Beran M, O'Brien S, Thomas D, et al. Phase I study of oral topotecan in hematological malignancies. Clin Cancer Res. 2003;9:4084-4091.
    • (2003) Clin Cancer Res , vol.9 , pp. 4084-4091
    • Beran, M.1    O'Brien, S.2    Thomas, D.3
  • 15
    • 0032884937 scopus 로고    scopus 로고
    • Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
    • Beran M, Estey E, O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999;17:2819-2830.
    • (1999) J Clin Oncol , vol.17 , pp. 2819-2830
    • Beran, M.1    Estey, E.2    O'Brien, S.3
  • 16
    • 1542753559 scopus 로고    scopus 로고
    • Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
    • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-4649.
    • (2003) J Clin Oncol , vol.21 , pp. 4642-4649
    • Cheson, B.D.1    Bennett, J.M.2    Kopecky, K.J.3
  • 17
    • 33745968917 scopus 로고    scopus 로고
    • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    • Cheson BD, Greenberg PL, M. Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419-425.
    • (2006) Blood , vol.108 , pp. 419-425
    • Cheson, B.D.1    Greenberg, P.L.2    Bennett, J.M.3
  • 19
    • 0034846008 scopus 로고    scopus 로고
    • Intravenous bolus topotecan in patients with myelodysplastic syndrome
    • Seiter K, Liu D, Feldman EJ, et al. Intravenous bolus topotecan in patients with myelodysplastic syndrome. Leuk Lymphoma. 2001;42:963-968.
    • (2001) Leuk Lymphoma , vol.42 , pp. 963-968
    • Seiter, K.1    Liu, D.2    Feldman, E.J.3
  • 20
    • 28844503525 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: A Cancer and Leukemia Group B study
    • Klein CE, Kastrissios H, Miller AA, et al. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006;57:199-206.
    • (2006) Cancer Chemother Pharmacol , vol.57 , pp. 199-206
    • Klein, C.E.1    Kastrissios, H.2    Miller, A.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.